Human UBQLN2 (Ubiquilin-2) ELISA Kit
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
Documents del producto
Product specifications
| Category | ELISA Kits |
| Reactivity | Human |
| Detection Method | Colorimetric |
| Assay Data | 4 hours |
| Assay Type | Sandwich ELISA, Double Antibody |
| Test Range | 78.125-5000pg/ml |
| Sensitivity | 46.875pg/ml |
| Size 1 | 96T |
| Tested Applications | ELISA |
| Sample Type | Serum, Plasma, Cell Culture Supernatant, cell or tissue lysate, Other liquid samples |
| Availability | Shipped within 10-14 working days. |
| Storage | 2-8 °C for 12 months |
| UniProt ID | Q9UHD9 |
| Alias | Ubiquilin-2, Chap1, DSK2 homolog, Protein linking IAP with cytoskeleton 2, PLIC-2, hPLIC-2, Ubiquitin-like product Chap1/Dsk2, UBQLN2, N4BP4, PLIC2 |
| Background | Elisa kits for UBQLN2 |
| Status | RUO |
Related Products
Human UBQLN2 (Ubiquilin-2) ELISA Kit
Ver Producto
UBQLN2 antibody
Plays an important role in the regulation of different protein degradation mechanisms and pathways including ubiquitin-proteasome system(UPS), autophagy and the endoplasmic reticulum-associated protein degradation(ERAD) pathway. Mediates the proteasomal targeting of misfolded or accumulated proteins for degradation by binding(via UBA domain) to their polyubiquitin chains and by interacting(via ubiquitin-like domain) with the subunits of the proteasome(PubMed:10983987). Plays a role in the ERAD pathway via its interaction with ER-localized proteins FAF2/UBXD8 and HERPUD1 and may form a link between the polyubiquitinated ERAD substrates and the proteasome(PubMed:24215460, PubMed:18307982). Involved in the regulation of macroautophagy and autophagosome formation; required for maturation of autophagy-related protein LC3 from the cytosolic form LC3-I to the membrane-bound form LC3-II and may assist in the maturation of autophagosomes to autolysosomes by mediating autophagosome-lysosome fusion(PubMed:19148225, PubMed:20529957). Negatively regulates the endocytosis of GPCR receptors: AVPR2 and ADRB2, by specifically reducing the rate at which receptor-arrestin complexes concentrate in clathrin-coated pits(CCPs)(PubMed:18199683).
Ver Producto